EP1082459A1 - Technique de diagnostic, de suivi et de stadification du cancer du poumon - Google Patents

Technique de diagnostic, de suivi et de stadification du cancer du poumon

Info

Publication number
EP1082459A1
EP1082459A1 EP99921894A EP99921894A EP1082459A1 EP 1082459 A1 EP1082459 A1 EP 1082459A1 EP 99921894 A EP99921894 A EP 99921894A EP 99921894 A EP99921894 A EP 99921894A EP 1082459 A1 EP1082459 A1 EP 1082459A1
Authority
EP
European Patent Office
Prior art keywords
lsg
levels
cancer
patient
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99921894A
Other languages
German (de)
English (en)
Other versions
EP1082459A4 (fr
Inventor
Fei Yang
Roberto A. Macina
Yongming Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Publication of EP1082459A1 publication Critical patent/EP1082459A1/fr
Publication of EP1082459A4 publication Critical patent/EP1082459A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Definitions

  • a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as LSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.
  • Lngl07 being a diagnostic marker for lung cancer.
  • the amino acid sequence encoded by Lngl07 is depicted in SEQ ID NO: 9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne une technique permettant de faire la détection, le diagnostic, le suivi, la stadification et le progonostic du cancer du poumon.
EP99921894A 1998-05-21 1999-05-12 Technique de diagnostic, de suivi et de stadification du cancer du poumon Withdrawn EP1082459A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8621298P 1998-05-21 1998-05-21
US86212P 1998-05-21
PCT/US1999/010344 WO1999060160A1 (fr) 1998-05-21 1999-05-12 Technique de diagnostic, de suivi et de stadification du cancer du poumon

Publications (2)

Publication Number Publication Date
EP1082459A1 true EP1082459A1 (fr) 2001-03-14
EP1082459A4 EP1082459A4 (fr) 2002-09-25

Family

ID=22197037

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99921894A Withdrawn EP1082459A4 (fr) 1998-05-21 1999-05-12 Technique de diagnostic, de suivi et de stadification du cancer du poumon

Country Status (4)

Country Link
EP (1) EP1082459A4 (fr)
JP (1) JP3688585B2 (fr)
CA (1) CA2328138A1 (fr)
WO (1) WO1999060160A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
CA2347656A1 (fr) * 1998-08-04 2000-02-17 Diadexus, Inc. Nouveau procede de diagnostic, de surveillance, de classification par stades, d'imagerie et de traitement du cancer des poumons
EP2053129A3 (fr) * 1998-09-02 2009-08-19 Diadexus, Inc. Procédé de diagnostic, surveillance, stratification, imagerie et traitement de divers cancers
US20020004206A1 (en) * 1999-04-09 2002-01-10 Berger Barry M. Methods of screening for disease
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001053349A2 (fr) 2000-01-21 2001-07-26 Ludwig Institute For Cancer Research Antigenes associes au cancer du poumon a petites cellules et utilisations de ces antigenes
AU2001241656A1 (en) * 2000-02-17 2001-08-27 Diadexus, Inc. Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
US20020119156A1 (en) * 2000-03-29 2002-08-29 Sei-Yu Chen Compositions and methods of diagnosing, monitoring, staging, imaging and treating lung cancer
AU2001277937A1 (en) * 2000-07-21 2002-02-05 Diadexus, Inc. Compositions and methods relating to lung specific genes
JP2004520814A (ja) * 2000-08-28 2004-07-15 ディアデクサス インコーポレーテッド 肺特異的遺伝子に関する組成物および方法
WO2002077236A2 (fr) * 2000-10-26 2002-10-03 Diadexus, Inc. Compositions et procedes associes aux genes et aux proteines specifiques du poumon
WO2002068633A2 (fr) * 2000-11-22 2002-09-06 Diadexus, Inc. Compositions et procedes concernant des genes et proteines specifiques aux poumons
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
US7332590B2 (en) 2001-08-16 2008-02-19 The United States Of America As Represented By The Department Of Health And Human Services Molecular characteristics of non-small cell lung cancer
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006013012A2 (fr) * 2004-08-04 2006-02-09 Bayer Healthcare Ag Diagnostics et therapeutique pour maladies liees a la napsine 1 (nap1)
WO2006047787A2 (fr) 2004-10-27 2006-05-04 Exact Sciences Corporation Methode de surveillance de la progression ou la recurrence d'une maladie
WO2006113467A2 (fr) 2005-04-14 2006-10-26 The Trustees Of Boston University Diagnostic des troubles pulmonaires mettant en oeuvre la prediction de categories
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
WO2007103541A2 (fr) 2006-03-09 2007-09-13 The Trustees Of Boston University Méthodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de gènes de cellules épithéliales nasales
EP2193211A4 (fr) 2007-09-19 2010-12-08 Univ Boston Identification de nouvelles voies pour le développement de médicaments destinés à traiter une maladie des poumons
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
EP3626308A1 (fr) 2013-03-14 2020-03-25 Veracyte, Inc. Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039419A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Genes et proteines specifiques du colon
WO1999036550A2 (fr) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines
WO2000000610A2 (fr) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Proteines contenant un peptide signal humain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939265A (en) * 1996-11-05 1999-08-17 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
EP0972056A1 (fr) * 1997-01-31 2000-01-19 Abbott Laboratories Reactifs et procedes utiles pour detecter des maladies du poumon

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039419A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Genes et proteines specifiques du colon
WO1999036550A2 (fr) * 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines
WO2000000610A2 (fr) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Proteines contenant un peptide signal humain

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [Online] March 1998 (1998-03) WANG Z ET AL: "ÄExpression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes]" Database accession no. NLM11263354 XP002206076 & ZHONGHUA JIE HE HE HU XI ZA ZHI = CHINESE JOURNAL OF TUBERCULOSIS AND RESPIRATORY DISEASES. CHINA MAR 1998, vol. 21, no. 3, March 1998 (1998-03), pages 164-166, ISSN: 1001-0939 *
See also references of WO9960160A1 *

Also Published As

Publication number Publication date
CA2328138A1 (fr) 1999-11-25
WO1999060160A1 (fr) 1999-11-25
EP1082459A4 (fr) 2002-09-25
JP3688585B2 (ja) 2005-08-31
JP2002515262A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
WO1999060160A1 (fr) Technique de diagnostic, de suivi et de stadification du cancer du poumon
CN107326066B (zh) 用于膀胱癌检测的尿标记物
EP2430193B1 (fr) Marqueurs de détection de cancers gastriques
EP1080227B1 (fr) Procédé de diagnostic, de surveillance et de détermination du stade du cancer du colon
CA2322023A1 (fr) Nouveau procede de detection et de surveillance d'un cancer endometrial ou uterin
JP3524061B2 (ja) 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法
JP3677210B2 (ja) 前立腺がんを診断し、モニターし、そして病期決定する新規な方法
JP2002525031A (ja) 大腸癌の診断、監視、病期決定、画像処理及び治療の新規方法
US7713693B1 (en) Human cancer cell specific gene transcript
US6949339B1 (en) Method of diagnosing, monitoring, and staging colon cancer
US7160679B1 (en) Method of diagnosing, monitoring, and staging lung cancer
US6861215B1 (en) Method of diagnosing, monitoring, and staging prostate cancer
AU2020200168A1 (en) Urine markers for detection of bladder cancer
JP2020072705A (ja) 膀胱癌を検出するための尿マーカー
JP2002526760A (ja) 消化器癌を診断、監視、病期分類、イメージング及び治療する新規な方法
AU2015200982A1 (en) Urine markers for detection of bladder cancer
US20220064235A1 (en) Urine Markers and Methods for Detection of Bladder Cancer and Treatment Thereof
EP1621639A2 (fr) Nouveau procédé de diagnostic, de surveillance et de stadification du cancer de la prostate
KR20230119346A (ko) 흑색종 치료 내성 예측용 trim51 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIADEXUS, INC.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7G 01N 33/72 B, 7G 01N 33/574 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020809

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050504